Thermo Fisher Scientific Inc.
TMO
$459.30
$6.701.48%
NYSE
| 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.20B | 44.56B | 43.74B | 43.21B | 42.90B |
| Total Other Revenue | 1.00M | 1.00M | 1.00M | 1.00M | -- |
| Total Revenue | 45.20B | 44.56B | 43.74B | 43.21B | 42.90B |
| Cost of Revenue | 26.70B | 26.26B | 25.64B | 25.37B | 25.12B |
| Gross Profit | 18.50B | 18.30B | 18.10B | 17.84B | 17.77B |
| SG&A Expenses | 8.60B | 8.53B | 8.47B | 8.45B | 8.50B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -134.00M | -135.00M | 30.00M | 30.00M | 30.00M |
| Total Operating Expenses | 36.56B | 36.05B | 35.55B | 35.26B | 35.05B |
| Operating Income | 8.64B | 8.51B | 8.18B | 7.95B | 7.85B |
| Income Before Tax | 7.39B | 7.27B | 7.12B | 7.02B | 6.99B |
| Income Tax Expenses | 522.00M | 547.00M | 544.00M | 436.00M | 472.00M |
| Earnings from Continuing Operations | 6.87K | 6.72K | 6.58K | 6.58K | 6.52K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -18.00M | -17.00M | -5.00M | 0.00 | -4.00M |
| Net Income | 6.85B | 6.70B | 6.57B | 6.58B | 6.52B |
| EBIT | 8.64B | 8.51B | 8.18B | 7.95B | 7.85B |
| EBITDA | 11.45B | 11.29B | 10.98B | 10.82B | 10.82B |
| EPS Basic | 18.21 | 17.76 | 17.33 | 17.32 | 17.10 |
| Normalized Basic EPS | 13.45 | 13.23 | 12.81 | 12.42 | 12.17 |
| EPS Diluted | 18.20 | 17.75 | 17.31 | 17.29 | 17.05 |
| Normalized Diluted EPS | 13.43 | 13.22 | 12.79 | 12.39 | 12.13 |
| Average Basic Shares Outstanding | 1.50B | 1.51B | 1.52B | 1.52B | 1.52B |
| Average Diluted Shares Outstanding | 1.51B | 1.51B | 1.52B | 1.52B | 1.53B |
| Dividend Per Share | 1.76 | 1.72 | 1.68 | 1.64 | 1.60 |
| Payout Ratio | 9.48% | 9.49% | 9.48% | 9.26% | 9.16% |